Journal of Fungi | Highly Cited Papers Published in 2024–2025 on Antifungal Drugs

To keep you informed of recent advancements in the study of antifungal drugs, the Journal of Fungi (JoF, ISSN 2309-608X) is pleased to present a selection of our most highly cited papers published in 2024 and 2025.

We hope that you find inspiration in these cutting-edge studies.

1. “Exploring Mechanisms of Antifungal Lipopeptide Iturin A from Bacillus against Aspergillus niger”
by Shiyi Wang, Min Xu, Ye Han and Zhijiang Zhou
J. Fungi 2024, 10(3), 172; https://doi.org/10.3390/jof10030172
Available online: https://www.mdpi.com/2309-608X/10/3/172

2. “Associations between Genomic Variants and Antifungal Susceptibilities in the Archived Global Candida auris Population”
by Yue Wang and Jianping Xu
J. Fungi 2024, 10(1), 86; https://doi.org/10.3390/jof10010086
Available online: https://www.mdpi.com/2309-608X/10/1/86

3. “Tracking Candidemia Trends and Antifungal Resistance Patterns across Europe: An In-Depth Analysis of Surveillance Systems and Surveillance Studies”
by Karin Odoc, Jacopo Garlasco, Maria Diletta Pezzani, Cristina Magnabosco, Diego Ortiz, Federica Manco, Liliana Galia, Sarah K. Foster, Fabiana Arieti and Evelina Tacconelli
J. Fungi 2024, 10(10), 685; https://doi.org/10.3390/jof10100685
Available online: https://www.mdpi.com/2309-608X/10/10/685

4. “New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions”
by Gustavo A. Niño-Vega, Leonardo Padró-Villegas and Everardo López-Romero
J. Fungi 2024, 10(12), 871; https://doi.org/10.3390/jof10120871
Available online: https://www.mdpi.com/2309-608X/10/12/871

5. “A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin”
by Ana Espinel-Ingroff and Nathan P. Wiederhold
J. Fungi 2024, 10(5), 362; https://doi.org/10.3390/jof10050362
Available online: https://www.mdpi.com/2309-608X/10/5/362

6. “The Molecular Basis of the Intrinsic and Acquired Resistance to Azole Antifungals in Aspergillus fumigatus”
by Parham Hosseini, Mikhail V. Keniya, Alia A. Sagatova, Stephanie Toepfer, Christoph Müller, Joel D. A. Tyndall, Anette Klinger, Edmond Fleischer and Brian C. Monk
J. Fungi 2024, 10(12), 820; https://doi.org/10.3390/jof10120820
Available online: https://www.mdpi.com/2309-608X/10/12/820

7. “Innovations in Antifungal Drug Discovery among Cell Envelope Synthesis Enzymes through Structural Insights”
by Yue Zhou and Todd B. Reynolds
J. Fungi 2024, 10(3), 171; https://doi.org/10.3390/jof10030171
Available online: https://www.mdpi.com/2309-608X/10/3/171

8. “Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris”
by Stephanie Toepfer, Mikhail V. Keniya, Michaela Lackner and Brian C. Monk
J. Fungi 2024, 10(10), 698; https://doi.org/10.3390/jof10100698
Available online: https://www.mdpi.com/2309-608X/10/10/698

9. “Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?”
by Paschalis Paranos, Ana Espinel-Ingroff and Joseph Meletiadis
J. Fungi 2024, 10(3), 214; https://doi.org/10.3390/jof10030214
Available online: https://www.mdpi.com/2309-608X/10/3/214

10. “Importance of the Aspergillus fumigatus Mismatch Repair Protein Msh6 in Antifungal Resistance Development”
by Jose Lucio, Irene Gonzalez-Jimenez, Alejandra Roldan, Jorge Amich, Laura Alcazar-Fuoli and Emilia Mellado
J. Fungi 2024, 10(3), 210; https://doi.org/10.3390/jof10030210
Available online: https://www.mdpi.com/2309-608X/10/3/210